RevvityRVTY
RVTY
About: Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.
Employees: 11,000
0
Funds holding %
of 7,245 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
65% more call options, than puts
Call options by funds: $1.93M | Put options by funds: $1.16M
20% more repeat investments, than reductions
Existing positions increased: 199 | Existing positions reduced: 166
16% more first-time investments, than exits
New positions opened: 57 | Existing positions closed: 49
4.45% more ownership
Funds ownership: 91.51% [Q4 2024] → 95.96% (+4.45%) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 6 [Q4 2024] → 6 (+0) [Q1 2025]
0% less funds holding
Funds holding: 518 [Q4 2024] → 517 (-1) [Q1 2025]
9% less capital invested
Capital invested by funds: $13.2B [Q4 2024] → $12B (-$1.22B) [Q1 2025]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$100
11%
upside
Avg. target
$114
27%
upside
High target
$125
39%
upside
7 analyst ratings
5 positive
71%
2 neutral
29%
0 negative
0%
UBS Dan Leonard | 28%upside $115 | Buy Upgraded | 1 May 2025 |
Goldman Sachs Matthew Sykes | 39%upside $125 | Buy Maintained | 29 Apr 2025 |
JP Morgan Rachel Vatnsdal | 11%upside $100 | Neutral Maintained | 29 Apr 2025 |
Raymond James Andrew Cooper | 33%upside $120 | Outperform Reiterated | 29 Apr 2025 |
Baird Catherine Ramsey | 39%upside $125 | Outperform Maintained | 29 Apr 2025 |
Financial journalist opinion
Based on 15 articles about RVTY published over the past 30 days
Neutral
Business Wire
3 days ago
Revvity's EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced the launch of its new IDS i20™ analytical random access platform from EUROIMMUN, enabling full automation of chemiluminescence immunoassays (ChLIA). The IDS i20 platform is a CE marked and FDA listed device that allows laboratories to consolidate multiple specialty tests on a unique single instrument with greater reagent capacity and higher test throughput compared to existing offerings. The highly versatile IDS i20 in.
Negative
Seeking Alpha
1 week ago
Revvity: Despite Facing Multiple Headwinds, Shares Are A Buy
Revvity faces multiple headwinds including declining biotech funding, regulatory uncertainty, and reduced academic research budgets. Despite challenges, Revvity's Q1 results beat expectations and the company maintained full-year guidance. While I rate Revvity a buy, it faces some structural challenges longer-term.
Neutral
Business Wire
3 weeks ago
Revvity to Present at Upcoming Investor Conferences
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences: Bank of America Global Healthcare Conference 2025 Tuesday, May 13, 2025 9:20 a.m. PT - Max Krakowiak, senior vice president and chief financial officer Goldman Sachs 46th Annual Global Healthcare Conference Tuesday, June 10, 2025 8:00 a.m. ET - Prahlad Singh, president and chief executive officer Attendees will receive an update on the Company and its strategic pri.
Positive
Zacks Investment Research
3 weeks ago
RVTY Rises as Q1 Earnings & Sales Beat Estimates, '25 Sales View Up
Revvity's first-quarter results showcase strong growth in Diagnostics business, along with recovery in Life Sciences segmental sales.
Neutral
Seeking Alpha
3 weeks ago
Revvity, Inc. (RVTY) Q1 2025 Earnings Call Transcript
Revvity, Inc. (NYSE:RVTY ) Q1 2025 Earnings Conference Call April 28, 2025 8:00 AM ET Company Participants Steve Willoughby - Senior Vice President, Investor Relations Prahlad Singh - President & Chief Executive Officer Max Krakowiak - Senior Vice President & Chief Financial Officer Conference Call Participants Patrick Donnelly - Citi Dan Brennan - TD Cowen Matt Sykes - Goldman Sachs Vijay Kumar - Evercore ISI Catherine Schulte - Baird Daniel Arias - Stifel Dan Leonard - UBS Luke Sergott - Barclays Tycho Peterson - Jefferies Operator Welcome everyone to Q1 2025 Revvity Earnings Conference Call. My name is Sammy, and I will be coordinating your call today.
Neutral
Zacks Investment Research
3 weeks ago
Revvity (RVTY) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Revvity (RVTY) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Positive
Benzinga
3 weeks ago
Life Science Tools Maker Revvity Delivers Strong Q1 Earnings Despite Evolving Macroeconomic Backdrop
Revvity Inc. RVTY stock is trading higher on Monday after the company reported better-than-expected first-quarter 2025 earnings.
Positive
Zacks Investment Research
3 weeks ago
Revvity (RVTY) Beats Q1 Earnings and Revenue Estimates
Revvity (RVTY) came out with quarterly earnings of $1.01 per share, beating the Zacks Consensus Estimate of $0.96 per share. This compares to earnings of $0.98 per share a year ago.
Positive
Reuters
3 weeks ago
Revvity beats quarterly estimates on steady demand for medical equipment
Revvity reported first-quarter results above Wall Street estimates and maintained its full-year profit forecast on Monday, helped by steady demand from biotech clients for medical equipment used for drug research.
Neutral
Business Wire
3 weeks ago
Revvity Announces Financial Results for the First Quarter of 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the first quarter ended March 30, 2025. The Company reported GAAP earnings per share of $0.35, as compared to $0.21 in the same period a year ago. Revenue for the quarter was $665 million, as compared to $650 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $72 million, as compared to $44 million for the same period a year ago. GAAP operati.
Charts implemented using Lightweight Charts™